| Primary | Number of Participants With Stent Thrombosis: Late | Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab. Timings: Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: >1 year post stent implantation | Intend To Treat population(ITT population) | Posted | | Count of Participants | | Participants | | 30 days to 1 year post stent implantation-Day 212 | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Secondary | Percent Diameter Stenosis (%DS) | In-segment, In-stent, Proximal and Distal. The value calculated as 100 * (1 - minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA). | | Posted | | Mean | Standard Deviation | Percent Diameter stenosis | | Pre-procedure | Number of lesions | Number of lesions | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Percent Diameter Stenosis (%DS) | In-segment, In-stent, Proximal and Distal. The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA). | | Posted | | Mean | Standard Deviation | Percent Diameter stenosis | | Immediately after the procedure | Number of lesions | Number of lesions | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Percent Diameter Stenosis (%DS) | In-segment, In-stent, Proximal and Distal. The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA). | The number of participants analyzed includes subjects who had available follow up data at that time frame. | Posted | | Mean | Standard Deviation | Percent Diameter Stenosis | | During follow-up, at 8 months post procedure | Number of lesions | Number of lesions | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants Using Antiplatelet Therapy | Number of patients using aspirin, clopidogrel, ticlopidine, cilostazol,prasugrel, compounding agents and other agents. | | Posted | | Count of Participants | | Participants | | At baseline before procedure | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants Using Antiplatelet Therapy | Number of patients using aspirin, clopidogrel, ticlopidine, cilostazol,prasugrel, compounding agents and other agents. | | Posted | | Count of Participants | | Participants | | Date of discharge from procedure day | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants Using Antiplatelet Therapy | Number of patients using aspirin, clopidogrel, ticlopidine, cilostazol,prasugrel, compounding agents and other agents. | | Posted | | Count of Participants | | Participants | | 8 months observation day from the procedure day | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants Using Antiplatelet Therapy | Number of patients using aspirin, clopidogrel, ticlopidine, cilostazol,prasugrel, compounding agents and other agents. | | Posted | | Count of Participants | | Participants | | 1 year observation day from the procedure day | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants Using Antiplatelet Therapy | Number of patients using aspirin, clopidogrel, ticlopidine, cilostazol,prasugrel, compounding agents and other agents. | The number of participants analyzed includes subjects who had available follow up data at that time frame. | Posted | | Count of Participants | | Participants | | 2 years observation day from the procedure day | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants Using Antiplatelet Therapy | Number of patients using aspirin, clopidogrel, ticlopidine, cilostazol,prasugrel, compounding agents and other agents. | The number of participants analyzed includes subjects who had available follow up data at that time frame. | Posted | | Count of Participants | | Participants | | 3 years observation day from the procedure day | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants Using Antiplatelet Therapy | Number of patients using aspirin, clopidogrel, ticlopidine, cilostazol,prasugrel, compounding agents and other agents. | The number of participants analyzed includes subjects who had available follow up data at that time frame. | Posted | | Count of Participants | | Participants | | 4 years observation day from the procedure day | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants Using Antiplatelet Therapy | Number of patients using aspirin, clopidogrel, ticlopidine, cilostazol,prasugrel, compounding agents and other agents. | The number of participants analyzed includes subjects who had available follow up data at that time frame. | Posted | | Count of Participants | | Participants | | 5 years observation day from the procedure day | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Death | All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
- Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
- Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
- Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
| | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death | All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
- Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
- Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
- Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
| | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death | All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
- Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
- Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
- Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
| | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death | All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
- Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
- Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
- Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
| | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death | All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
- Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
- Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
- Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
| | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death | All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
- Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
- Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
- Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
| | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death | All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
- Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
- Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
- Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
| | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Target Lesion Revascularization Based on Ischemia Findings | Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Target Lesion Revascularization Based on Ischemia Findings | Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Revascularization Based on Ischemia Findings | Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Revascularization Based on Ischemia Findings | Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Revascularization Based on Ischemia Findings | Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Revascularization Based on Ischemia Findings | Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Revascularization Based on Ischemia Findings | Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Myocardial Infarction | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Myocardial Infarction | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Myocardial Infarction | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Myocardial Infarction | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Myocardial Infarction | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Myocardial Infarction | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Myocardial Infarction | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Cardiac Death | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.) | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.) | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.) | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.) | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.) | | Posted | | Count of Participants | | Participants | | 0 to 3 Years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.) | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.) | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With MI Related to Target Vessel | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With MI Related to Target Vessel | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With MI Related to Target Vessel | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With MI Related to Target Vessel | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With MI Related to Target Vessel | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With MI Related to Target Vessel | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With MI Related to Target Vessel | Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Death,Myocardial Infarction and Revascularization (DMR) | DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization. | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Death,Myocardial Infarction and Revascularization (DMR) | DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization. | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Death,Myocardial Infarction and Revascularization (DMR) | DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization. | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Death,Myocardial Infarction and Revascularization (DMR) | DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization. | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Death,Myocardial Infarction and Revascularization (DMR) | DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization. | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Death,Myocardial Infarction and Revascularization (DMR) | DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization. | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Death,Myocardial Infarction and Revascularization (DMR) | DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization. | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With All Revascularization | All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR. | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With All Revascularization | All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR. | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With All Revascularization | All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR. | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With All Revascularization | All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR. | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With All Revascularization | All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR. | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With All Revascularization | All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR. | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With All Revascularization | All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR. | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Failure (TVF) | Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Failure (TVF) | Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Failure (TVF) | Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Failure (TVF) | Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Failure (TVF) | Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Failure (TVF) | Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Failure (TVF) | Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (Non-TLR) | Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR. | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (Non-TLR) | Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR. | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (Non-TLR) | Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR. | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (Non-TLR) | Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR. | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (Non-TLR) | Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR. | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (Non-TLR) | Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR. | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (Non-TLR) | Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR. | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (TLR or TVR (Non-TLR)) | Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, nonTLR). | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (TLR or TVR (Non-TLR)) | Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, nonTLR). | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (TLR or TVR (Non-TLR)) | Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, nonTLR). | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (TLR or TVR (Non-TLR)) | Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, nonTLR). | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (TLR or TVR (Non-TLR)) | Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, nonTLR). | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (TLR or TVR (Non-TLR)) | Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, nonTLR). | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Vessel Revascularization (TLR or TVR (Non-TLR)) | Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, nonTLR). | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE) | Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE) | Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE) | Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE) | Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE) | Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE) | Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE) | Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death/All MI | All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death or Target-Vessel MI | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death or Target-Vessel MI | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death or Target-Vessel MI | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death or Target-Vessel MI | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death or Target-Vessel MI | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death or Target-Vessel MI | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Cardiac Death or Target-Vessel MI | Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Number of Participants With Target Lesion Failure (TLF) | TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | During hospitalization | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Failure (TLF) | TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 8 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Failure (TLF) | TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 1 year | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Failure (TLF) | TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 2 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Failure (TLF) | TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 3 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Failure (TLF) | TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 4 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Number of Participants With Target Lesion Failure (TLF) | TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR). | | Posted | | Count of Participants | | Participants | | 0 to 5 years | | | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | |
| Secondary | Mean Acute Gain: In-stent, In-segment | The difference between post- and pre-procedural MLD. | | Posted | | Mean | Standard Deviation | mm | | At 8 months, post index procedure | Number of lesions QCA | Number of lesions QCA | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | Units | Counts |
|---|
| Participants | | | Number of lesions QCA | |
|
| Secondary | Mean Late Loss(LL): In-stent, In-segment, Proximal, and Distal | Late loss is calculated as MLD post procedure - MLD at follow-up. | | Posted | | Mean | Standard Deviation | mm | | At 8 months, post index procedure | Number of lesions QCA | Number of lesions QCA | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | Units | Counts |
|---|
| Participants | | | Number of lesions QCA | |
|
| Secondary | Mean Net Gain: In-stent, In-segment | Late procedural outcome is influenced by both the acute gain provided by the intervention (pre to post) and the subsequent late loss that occurs after the intervention (post to follow-up).The net gain is thus the sum of the offsetting effects of acute gain and late loss (net gain = acute gain - late loss). | | Posted | | Mean | Standard Deviation | mm | | At 8 months, post index procedure | Number of lesions QCA | Number of lesions QCA | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| |
| Secondary | Mean Lesion Length | The lesion length will be measured by QCA. | | Posted | | Mean | Standard Deviation | mm | | Pre-procedure | Number of lesions QCA | Number of lesions QCA | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | Units | Counts |
|---|
| Participants | | | Number of lesions QCA | |
|
| Secondary | Minimum Blood Vessel Diameter | Minimum blood vessel diameter measured by QCA | | Posted | | Mean | Standard Deviation | mm | | Pre-procedure | Number of lesions QCA | Number of lesions QCA | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | Units | Counts |
|---|
| Participants | | | Number of lesions QCA | |
|
| Secondary | Minimum Blood Vessel Diameter | Minimum blood vessel diameter measured by QCA | | Posted | | Mean | Standard Deviation | mm | | Immediately after the procedure | Number of lesions QCA | Number of lesions QCA | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | Units | Counts |
|---|
| Participants | | | Number of lesions QCA | |
|
| Secondary | Minimum Blood Vessel Diameter | Minimum blood vessel diameter measured by QCA | The number of participants analyzed includes subjects who had available follow up data at that time frame. | Posted | | Mean | Standard Deviation | mm | | During follow-up, at 8 months post procedure | Number of lesions QCA | Number of lesions QCA | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | Units | Counts |
|---|
| Participants | | | Number of lesions QCA |
|
| Secondary | Mean Reference Vessel Diameter (RVD) | Reference vessel diameter measured by QCA | | Posted | | Mean | Standard Deviation | mm | | Pre-procedure | Number of lesions | Number of lesions | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | Units | Counts |
|---|
| Participants | | | Number of lesions | |
|
| Secondary | Mean Reference Vessel Diameter (RVD) | Reference vessel diameter measured by QCA | | Posted | | Mean | Standard Deviation | mm | | Immediately after the procedure | Number of lesions QCA | Number of lesions QCA | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | Units | Counts |
|---|
| Participants | | | Number of lesions QCA | |
|
| Secondary | Mean Reference Vessel Diameter (RVD) | Reference vessel diameter measured by QCA | The number of participants analyzed includes subjects who had available follow up data at that time frame. | Posted | | Mean | Standard Deviation | mm | | During follow-up, at 8 months post procedure | Number of lesions QCA | Number of lesions QCA | | ID | Title | Description |
|---|
| OG000 | XIENCE Xpedition 2.25 mm Stent Arm | Patients receiving XIENCE Xpedition 2.25 mm stent |
| | Units | Counts |
|---|
| Participants | | | Number of lesions QCA |
|